Drug
BI 1015550
Status:
Phase 3
Condition:
Other ILD
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Detail
BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects.
Study Purpose
This study is open to adults with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study.
The purpose of this study is to find out whether a medicine called BI 1015550 helps people with PF-ILD.